Results 41 to 50 of about 1,760 (179)

Mucopolysaccharidosis IVA: Current Disease Models and Drawbacks

open access: yes, 2023
Mucopolysaccharidosis IVA (MPS IVA) is a rare disorder caused by mutations in the N-acetylgalactosamine-6-sulfate-sulfatase (GALNS) encoding gene. GALNS leads to the lysosomal degradation of the glycosaminoglyccreasans keratan sulfate and chondroitin 6 ...
Andrés Felipe Leal   +2 more
core   +2 more sources

Biochemical diagnosis of mucopolysaccharidosis in a Mexican reference center [PDF]

open access: yesGenetics and Molecular Biology, 2020
Mucopolysaccharidoses (MPS) are a group of genetic disorders, each resulting from the deficiency of one of the lysosomal enzymes that catabolizes mucopolysaccharides.
Sandra del Carmen Mendoza-Ruvalcaba   +4 more
doaj   +2 more sources

Bone Growth Induction in Mucopolysaccharidosis IVA Mouse

open access: yes, 2023
Mucopolysaccharidosis IVA (MPS IVA; Morquio A syndrome) is caused by a deficiency of the N-acetylgalactosamine-6-sulfate-sulfatase (GALNS) enzyme, leading to the accumulation of glycosaminoglycans (GAG), keratan sulfate (KS) and chondroitin-6-sulfate ...
Nidhi, Fnu   +6 more
core   +2 more sources

The landscape of Mucopolysaccharidosis in Southern and Eastern European countries: a survey from 19 specialistic centers

open access: yesOrphanet Journal of Rare Diseases, 2022
Background Mucopolysaccharidoses (MPS) are a group of lysosomal storage disorders caused by defects in genes coding for different lysosomal enzymes which degrade glycosaminoglycans.
Anna Tylki-Szymańska   +17 more
doaj   +1 more source

Chondroitin sulfate disaccharide is a specific and sensitive biomarker for mucopolysaccharidosis type IVA

open access: yesJIMD Reports, 2020
Mucopolysaccharidosis type IVA (MPS IVA) is an inborn error of glycosaminoglycan (GAG) catabolism characterized by a deficiency of the lysosomal enzyme, N‐acetylgalactosamine 6‐sulphatase (GALNS).
Sharon J. Chin   +5 more
doaj   +1 more source

Baseline Biometric Characteristics of MPS IVA Patients (n = 54).

open access: yes, 2016
Baseline Biometric Characteristics of MPS IVA Patients (n = 54).
Christina Lampe (426094)   +7 more
core   +1 more source

Valve Involvement in MPS IVA Patients (n = 54).

open access: yes, 2016
Valve Involvement in MPS IVA Patients (n = 54).
Christina Lampe (426094)   +7 more
core   +1 more source

Role of elosulfase alfa in mucopolysaccharidosis IVA

open access: yes, 2016
Debra S Regier, Pranoot Tanpaiboon Division of Genetics and Metabolism, Children’s National Medical Center, Washington, DC, USA Abstract: Mucopolysaccharidosis type IVA (MPS IVA or Morquio A) is an autosomal recessive lysosomal storage disease
Regier, Debra S.   +3 more
core   +1 more source

Atmospheric Deposition of Organic Pollutants: A Comprehensive Review of Sampling and Analytical Methodologies

open access: yesAnalytical Science Advances, Volume 7, Issue 1, June 2026.
ABSTRACT Atmospheric deposition of organic pollutants plays a crucial role in the transport and fate of contaminants in the environment, with implications for ecosystem health and human exposure. Persistent organic pollutants (POPs), polycyclic aromatic hydrocarbons (PAHs) and microplastics are increasingly recognized as transboundary threats due to ...
Iva Smoljo   +2 more
wiley   +1 more source

Expert‐Designed Fact Sheets and AI‐Based Analysis of Patient Symptoms to Combat Diagnostic Delays in Inherited Metabolic Diseases

open access: yesJournal of Inherited Metabolic Disease, Volume 49, Issue 2, March 2026.
ABSTRACT The importance of early diagnosis of inherited metabolic diseases (IMDs) is well known, as it allows early intervention to prevent or reduce complications and improve prognosis, since many of these disorders are treatable. However, diagnosis can still be delayed, and many patients remain undiagnosed. Reducing diagnosis delays is a primary goal
Aline Cano   +108 more
wiley   +1 more source

Home - About - Disclaimer - Privacy